Pulling SEC filings + quote and writing the call…

LIGHTBRIDGE Corp
Next earnings Aug 10, 2026
Last earnings +4.1% on 2026-04-27
A pre-revenue nuclear-fuel science project with a fortress balance sheet but no commercial product — a bet, not an investable business.
Revenue (FY2025) $0.00 · FY2025
Lightbridge is a development-stage company, not an operating business. It has booked $0.00 in revenue every year on record (FY2021 through FY2025), and the losses are accelerating, not narrowing: net loss widened from -$7.84M (FY2021) to -$19.6M (FY2025), with operating loss deepening to -$23.2M as G&A rose 65% and R&D doubled (+100%) year-over-year. The MD&A is explicit that management expects to 'significantly increase our R&D spend in the near future,' so the burn is designed to grow. There is no top line to value the company on, no margins to analyze, and returns on capital are negative (ROE -9.6%). Every product milestone described — fuel fabrication, irradiation testing, the Oklo co-location study, cladding-alloy work — is years of technical and regulatory risk away from any revenue.
The one genuine strength is the balance sheet, and it is a real one. The company raised heavily during FY2025 (shares outstanding +67.8%, cash +404.8%, equity +400.9%), leaving $202M in cash against just $1.15M-scale liabilities (liabilities/equity 0.01x). Against ~-$14.3M of annual operating cash burn, that is many years of runway, and interest income ($3.6M in FY2025) now meaningfully offsets the loss. This is not a company at risk of failing for lack of cash in the near term. But that capital came at a cost to existing holders — the 67.8% share-count increase is heavy dilution, and with an accumulated deficit of -$184M and rising spend, more raises are likely.
Is LTBR a buy? The one-page verdict, explained →
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$7.88M | -$7.79M | -$9.04M | -$13.1M | -$23.2M |
| Net income | -$7.84M | -$7.50M | -$7.91M | -$11.8M | -$19.6M |
| Diluted EPS | -$1.71 | -$0.69 | -$0.65 | -$0.81 | — |
| Net margin | — | — | — | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Annual meeting vote results: director slate and routine proposals approved
Q1 2026: no revenue, continued loss, ~$200M cash, debt-free balance sheet
Q1 2026 results: still pre-revenue with ongoing net loss; ~$200M cash intact
FY2025 10-K: loss widened to $19.6M on higher R&D/G&A; $202M cash, no debt
FY2025 results: net loss widened 66% to $19.6M, zero revenue
Q3 2025: pre-revenue dev-stage loss; cash cushion funds fuel R&D
Q3 2025 results: pre-revenue net loss as R&D spend ramps
Other-event disclosure, likely a fuel-development or partnership update
Sources: SEC EDGAR (CIK 0001084554, latest 10-Q filed 2026-04-30) · EODHD · Proprietary analysis · as of 7/3/2026, 10:31:32 AM.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 3, 2026, 6:31 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 0 open-market buys · 3 sales
| 2026-07-01 | Chakraborty Sweta Director | Sell | 1.14K @ $9.29 | $10.6K |
| 2026-07-01 | Goodman Sherri Director | Sell | 1.12K @ $9.29 | $10.4K |
| 2026-06-22 | Goodman Sherri Director | Sell | 1.12K @ $9.58 | $10.7K |
| 2026-04-03 | GOLDMAN LARRY CFO | Tax | 9.01K @ $11.09 | $100.0K |
| 2026-04-03 | MUSHAKOV ANDREY EVP, Nuclear Operations | Tax | 8.60K @ $11.09 | $95.3K |
| 2026-04-03 | GRAE SETH President and CEO | Tax | 13.3K @ $11.09 | $147K |
| 2026-01-29 | MUSHAKOV ANDREY EVP, Nuclear Operations | Sell | 2.53K @ $17.48 | $44.3K |
| 2026-01-29 | MUSHAKOV ANDREY EVP, Nuclear Operations | Sell | 24.9K @ $16.54 | $412K |
| 2026-01-29 | MUSHAKOV ANDREY EVP, Nuclear Operations | Sell | 2.83K @ $16.03 | $45.3K |
| 2026-01-15 | GOLDMAN LARRY CFO | Sell | 6.35K @ $18.07 | $115K |
| 2026-01-14 | GOLDMAN LARRY CFO | Sell | 2.52K @ $18.00 | $45.3K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1195 tracked peers · median